A prospective trial will investigate the efficacy and safety of epratuzumab as a thorium-227-labeled antibody in patients with advanced non-Hodgkin's lymphoma

Trial Profile

A prospective trial will investigate the efficacy and safety of epratuzumab as a thorium-227-labeled antibody in patients with advanced non-Hodgkin's lymphoma

Planning
Phase of Trial: Phase II

Latest Information Update: 02 Mar 2016

At a glance

  • Drugs Epratuzumab (Primary)
  • Indications Non-Hodgkin's lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 02 Mar 2016 New trial record
    • 26 Feb 2016 According to Immunomedics media release, Bayer started studying epratuzumab as a thorium-227-labeled antibody in patients with advanced non-Hodgkin lymphoma.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top